Ascendis Pharma's TransCon CNP is under U.S. FDA priority review, and the company aims to fulfill Vision 2030.
3 reports, 2 independent
Updated Aug 1
Gone quiet
- Reports
- 3
- Developments
- 2
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Ascendis Pharma's TransCon CNP is under U.S. FDA priority review, and the company aims to fulfill Vision 2030.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Collaboration between Novo Nordisk and Ascendis Pharma terminated regarding TransCon products.Sub-event
Ascendis Pharma's TransCon CNP is under FDA priority review.1 source
Keep exploring
The entities involved
- FDA
-
Vision 2030
Slovak company
- Vision 2030 is guiding the transformation of the real estate sector, supported by the Ministry of Municipalities and Housing in Saudi Arabia.
- Saudi Arabia is strategically transforming its economic relations, leveraging partnerships to support economic diversification efforts in line with Vision 2030, including coordination in oil markets.
Coverage
Newest first; wire copies grouped- manilatimes.net
- GlobeNewswireAscendis Pharma Reports Second Quarter 2025 Financial Results – Q2 2025 revenue of €103.0 million for YORVIPATH® and €50.7 million for SKYTROFA® – TransCon® CNP (navepegritide) NDA under Priority Rev
- Unknown outlet